Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Treatment of individuals exhibiting defective CD40L

Treatment of individuals exhibiting defective CD40L

US Patent 6106832 · Granted Aug 22, 2000

Estimated economic value: $576,630,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Anti-PD1 and anti-CTLA4 antibodies2024
Anti-mesothelin binding proteins2024
Fc-containing molecules exhibiting predictable, consistent, and reproducible gly2022
Anti-PD1 and anti-CTLA4 antibodies2021
Anti-mesothelin binding proteins2021
BCMA antigen binding proteins2019
BCMA antigen binding proteins2019
CD27L antigen binding proteins2019
BCMA Antigen binding proteins2019
BCMA Antigen binding proteins2019
Anti-mesothelin binding proteins2018
Human CD30 ligand antigen binding proteins2018